Prestige Consumer Healthcare Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Prestige Consumer Healthcare Inc.
After a company-record FY2022, Prestige CEO Ron Lombardi says future inflationary pressures and supply chain issues should be “manageable.”
Inflation's impact on consumer spending will be front and center in sector’s quarterly reports, beginning with J&J on 19 April. Potential impact also from price hikes common from most firms since early 2021 in response to increasing costs. Russia’s invasion of Ukraine also will prompt comment.
With approval, FDA created regulatory classification allowing subsequent devices of same type with same intended use may go through 510(k) pathway, allowing devices to obtain clearance by demonstrating substantial equivalence to a predicate device.
Cost increases initially spurred by supply chain disruptions by COVID-19 pandemic have been noted by businesses across consumer product industries since soon after novel coronavirus spread accelerated in early 2020. More recently, OTC drug, nutritional supplement and personal care product providers began noting inflation’s influence on costs.
- OTC, Consumer
- Other Names / Subsidiaries
- Prestige Brands, Inc.